Last CNY12.23 CNY
Change Today -0.16 / -1.29%
Volume 9.0M
As of 3:05 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

zhejiang huahai pharmaceut-a (600521) Snapshot

Open
CNY12.39
Previous Close
CNY12.39
Day High
CNY12.65
Day Low
CNY12.20
52 Week High
09/25/13 - CNY17.09
52 Week Low
04/29/14 - CNY9.78
Market Cap
9.6B
Average Volume 10 Days
8.0M
EPS TTM
CNY0.42
Shares Outstanding
785.3M
EX-Date
05/13/14
P/E TM
29.3x
Dividend
CNY0.20
Dividend Yield
1.64%
Current Stock Chart for ZHEJIANG HUAHAI PHARMACEUT-A (600521)

Related News

No related news articles were found.

zhejiang huahai pharmaceut-a (600521) Related Businessweek News

No Related Businessweek News Found

zhejiang huahai pharmaceut-a (600521) Details

Zhejiang Huahai Pharmaceutical Co., Ltd. manufactures and sells formulations, active pharmaceutical ingredients, and intermediates in China and internationally. It provides pril products, such as captopril, enalapril, and lisinopril. The company was founded in 1989 and is based in Linhai, China.

Founded in 1989

zhejiang huahai pharmaceut-a (600521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zhejiang huahai pharmaceut-a (600521) Key Developments

Zhejiang Huahai Pharmaceutical co Ltd, Board Meeting, Jun 28, 2014

Zhejiang Huahai Pharmaceutical co Ltd, Board Meeting, Jun 28, 2014. Agenda: To discuss and approve the proposal of conducting entrusted wealth management or entrusted loan business with idle self-owned funds; and to discuss and approve the proposal of adjusting exercise price of its stock option incentive plan.

Zhejiang Huahai Pharmaceutical co Ltd(SHSE:600521) added to SSE 180 Index

Zhejiang Huahai Pharmaceutical co Ltd will be added to the SSE 180 Index .

Zhejiang Huahai Pharmaceutical co Ltd Receives Approval from Food and Drug Administration to Sell High Blood Pressure Drug in US

Zhejiang Huahai Pharmaceutical Co. Ltd. revealed notice from the Food and Drug Administration (FDA), getting approval for Abbreviated New Drug Application (ANDA) of lrbesartan and Hydrochlorothiazide Tablets. The tablets are used for cure high blood pressure. The approval signals that the drug is okayed for sale in US from June 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600521:CH CNY12.23 CNY -0.16

600521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600521.
View Industry Companies
 

Industry Analysis

600521

Industry Average

Valuation 600521 Industry Range
Price/Earnings 29.9x
Price/Sales 4.2x
Price/Book 3.0x
Price/Cash Flow 31.5x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZHEJIANG HUAHAI PHARMACEUT-A, please visit www.huahaipharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.